Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carbetocin intranasal - Ferring Pharmaceuticals/Levo Therapeutics

Next Previous
Drug Profile

Carbetocin intranasal - Ferring Pharmaceuticals/Levo Therapeutics

Alternative Names: ACP-101; FE-992097; LV 101

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Levo Therapeutics
  • Class Antihaemorrhagics; Obesity therapies; Oxytocics; Posterior pituitary hormones
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prader-Willi syndrome

Most Recent Events

  • 24 Sep 2025 Efficacy and adverse events data from a phase-III clinical trials in Prader-Willi syndrome released by Acadia Pharmaceuticals
  • 30 Jun 2025 Acadia Pharmaceuticals completes enrolment in phase-III trial in Prader-Willi syndrome (In children, In adults, In adolescents) in Spain, Germany, France, Canada, United Kingdom and USA (Intranasal) (NCT06173531)
  • 11 Mar 2024 ACADIA Pharmaceuticals initiates enrolment in a phase III open-label extension trial in Prader-Willi syndrome (In children, In adolescents, in adults) in USA (Intranasal, Spray) (NCT06420297)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top